JP2013506687A - オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法 - Google Patents

オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法 Download PDF

Info

Publication number
JP2013506687A
JP2013506687A JP2012532326A JP2012532326A JP2013506687A JP 2013506687 A JP2013506687 A JP 2013506687A JP 2012532326 A JP2012532326 A JP 2012532326A JP 2012532326 A JP2012532326 A JP 2012532326A JP 2013506687 A JP2013506687 A JP 2013506687A
Authority
JP
Japan
Prior art keywords
autophagy
gene
disease
agent
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012532326A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013506687A5 (https=
Inventor
ユアン，ジュニング
エム リピンスキ，マルタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2013506687A publication Critical patent/JP2013506687A/ja
Publication of JP2013506687A5 publication Critical patent/JP2013506687A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
JP2012532326A 2009-09-30 2010-09-30 オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法 Pending JP2013506687A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24730909P 2009-09-30 2009-09-30
US24725109P 2009-09-30 2009-09-30
US61/247,251 2009-09-30
US61/247,309 2009-09-30
PCT/US2010/050968 WO2011041584A2 (en) 2009-09-30 2010-09-30 Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products

Publications (2)

Publication Number Publication Date
JP2013506687A true JP2013506687A (ja) 2013-02-28
JP2013506687A5 JP2013506687A5 (https=) 2013-11-14

Family

ID=43365297

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2012532326A Pending JP2013506687A (ja) 2009-09-30 2010-09-30 オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法
JP2012532325A Pending JP2013506686A (ja) 2009-09-30 2010-09-30 オートファジー阻害遺伝子産物の変調によりオートファジーを変調する方法
JP2015201268A Pending JP2016040297A (ja) 2009-09-30 2015-10-09 オートファジー阻害遺伝子産物の変調によりオートファジーを変調する方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012532325A Pending JP2013506686A (ja) 2009-09-30 2010-09-30 オートファジー阻害遺伝子産物の変調によりオートファジーを変調する方法
JP2015201268A Pending JP2016040297A (ja) 2009-09-30 2015-10-09 オートファジー阻害遺伝子産物の変調によりオートファジーを変調する方法

Country Status (11)

Country Link
US (4) US20120301463A1 (https=)
EP (2) EP2483407A2 (https=)
JP (3) JP2013506687A (https=)
KR (1) KR20120082906A (https=)
CN (2) CN102639700A (https=)
AU (2) AU2010300531A1 (https=)
BR (2) BR112012007137A2 (https=)
CA (2) CA2774999A1 (https=)
MX (1) MX2012003770A (https=)
RU (1) RU2012117230A (https=)
WO (2) WO2011041584A2 (https=)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8187802B2 (en) * 2008-11-19 2012-05-29 Rutgers, The State University Of New Jersey Cell lines useful for assessing modulation of autophagy
EP3563859B1 (en) 2012-08-13 2021-10-13 Cedars-Sinai Medical Center Cardiosphere-derived exosomes for tissue regeneration
CA2893824A1 (en) * 2012-12-14 2014-06-19 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of ckap5 by double-stranded rna
CN103990126A (zh) * 2013-02-17 2014-08-20 复旦大学 一种治疗肿瘤的增效药物组合物
CN103877103A (zh) * 2013-04-28 2014-06-25 中国人民解放军军事医学科学院放射与辐射医学研究所 Plcg1基因及其特异性抑制剂u73122抗辐射损伤的新用途
US20160136123A1 (en) * 2013-06-14 2016-05-19 Vojo P. Deretic Treatment of autophagy-related disorders
US20160272969A1 (en) * 2013-10-31 2016-09-22 Ilana (Helena) NATHAN Compositions and methods for modulating autophagic cell death
CN104826113B (zh) * 2014-02-12 2018-06-05 中国科学院上海生命科学研究院 抑制间充质干细胞自噬在自身免疫性疾病中的应用
EP4494699A3 (en) 2014-10-03 2025-04-30 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
KR101524426B1 (ko) * 2015-03-25 2015-05-29 경희대학교 산학협력단 자가포식 특이적 억제제 발굴을 위한 스크리닝 방법
WO2016164608A1 (en) 2015-04-07 2016-10-13 Alector Llc Methods of screening for sortilin binding antagonists
SI3280441T1 (sl) 2015-04-07 2022-01-31 Alector Llc Protitelesa anti-sortilin in metoda njihove uporabe
JP2017214302A (ja) * 2016-05-30 2017-12-07 国立大学法人 東京大学 オートファジー誘導剤
AU2017381585B2 (en) 2016-12-19 2025-02-13 Fundacio Privada Institucio Catalana de Recerca i Estudis Avancats Antibodies against LIF and uses thereof
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
JP7336769B2 (ja) 2017-04-19 2023-09-01 シーダーズ―シナイ メディカル センター 骨格筋ジストロフィーを治療する方法及び組成物
CN109420173B (zh) * 2017-08-31 2021-07-13 清华大学 Gpr55及其调节剂在防治免疫系统疾病中的应用
CN109420174B (zh) * 2017-08-31 2021-07-13 清华大学 Gpr18及其调节剂在防治免疫系统疾病中的应用
WO2019126068A1 (en) 2017-12-20 2019-06-27 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
EP3749344A4 (en) 2018-02-05 2022-01-26 Cedars-Sinai Medical Center METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS
CN108396036B (zh) * 2018-03-01 2021-08-03 昆明医科大学 一种过表达cox5a转基因鼠模型及其构建方法与应用
US20210130826A1 (en) * 2018-04-06 2021-05-06 Ionis Pharmaceuticals, Inc. Methods of modulating antisense activity
WO2019231188A1 (ko) * 2018-05-31 2019-12-05 주식회사 센트릭스바이오 Cd300c의 발현 억제제 또는 활성 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
KR102320280B1 (ko) * 2018-05-31 2021-11-29 주식회사 센트릭스바이오 CD300c의 발현 억제제 또는 활성 억제제를 포함하는 암 예방 또는 치료용 약학적 조성물
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
CN109481683B (zh) * 2018-12-19 2021-07-02 四川大学华西医院 α受体阻滞剂在制备治疗急性胰腺炎的药物中的应用
CN109628451A (zh) * 2019-01-10 2019-04-16 广西大学 一种抑制兔Deptor基因表达的shRNA、慢病毒表达载体及其构建方法和应用
CN110106182B (zh) * 2019-05-13 2023-01-10 华南农业大学 p65基因在猪卵巢颗粒细胞中的应用
CN110283766B (zh) * 2019-05-13 2020-12-18 华中科技大学 一种重组卡介苗及其构建与应用
EP4013883A1 (en) * 2019-08-16 2022-06-22 Janssen Biotech, Inc. Therapeutic immune cells with improved function and methods for making the same
CN110354131A (zh) * 2019-08-27 2019-10-22 刘磊 阿夫唑嗪在治疗或预防帕金森病及相关疾病中的用途
AU2020387199B2 (en) * 2019-11-18 2025-05-22 CentricsBio, Inc. Composition for preventing or treating cancer, comprising anti-CD300c monoclonal antibodies
KR102464507B1 (ko) * 2019-11-18 2022-11-09 주식회사 센트릭스바이오 항-CD300c 단클론 항체를 포함하는 암 예방 또는 치료용 조성물
CN110850088B (zh) * 2019-12-06 2021-08-20 四川大学华西医院 Gtf2ird2自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
KR102583540B1 (ko) * 2021-01-26 2023-10-06 한국과학기술연구원 퇴행성 뇌질환에서 zbtb16의 용도
WO2022163959A1 (ko) * 2021-01-26 2022-08-04 한국과학기술연구원 퇴행성 뇌질환에서 zbtb16의 용도
CN113077841B (zh) * 2021-03-01 2022-05-24 华中科技大学 一种预测调控酵母自噬的功能基因的方法
CN115068614A (zh) * 2021-03-12 2022-09-20 胡晓兰 用于诊断、治疗和预防癌症的方法和组合物
CA3218832A1 (en) * 2021-05-13 2022-11-17 CentricsBio, Inc. Combined therapy using anti-cd300c antibody
WO2023278802A1 (en) * 2021-07-01 2023-01-05 Cedars-Sinai Medical Center Formulations for oral delivery of nucleic acids
CN114702552B (zh) * 2022-03-11 2024-05-31 苏州思萃免疫技术研究所有限公司 mTORC2抑制剂
KR20230155978A (ko) * 2022-05-02 2023-11-13 주식회사 센트릭스바이오 항-CD300c 항체 또는 이의 항원 결합 단편 및 그의 퇴행성 뇌 질환 예방 또는 치료용 용도
CN115814080B (zh) * 2022-12-12 2023-07-07 安徽科技学院 一种含隐丹参酮的光动力治疗剂及其应用
CN116609528A (zh) * 2023-04-19 2023-08-18 华南理工大学 一种胰腺癌早期诊断标志物纽扣蛋白cingulin及抗癌药物新靶标

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008152816A1 (en) * 2007-06-14 2008-12-18 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of vegfr1 by smyd3

Family Cites Families (264)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6214334B1 (en) 1991-10-21 2001-04-10 Trustees Of The University Of Pennsylvania Compositions and methods for producing and using homogenous neuronal cell transplants to treat neurodegenerative disorders and brain and spinal cord injuries
US5681747A (en) 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
AU687010B2 (en) 1992-07-17 1998-02-19 Dana-Farber Cancer Institute Method of intracellular binding of target molecules
DE4239877C1 (de) 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
WO1995003832A1 (en) 1993-07-30 1995-02-09 Thomas Jefferson University Intracellular immunization
FR2721943B1 (fr) 1994-06-29 1996-08-02 Rhone Poulenc Rorer Sa Adenovirus comprenant un gene codant pour une superoxyde dismutase
US5556837A (en) 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
US5614649A (en) 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5853987A (en) 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
US5834457A (en) 1996-01-26 1998-11-10 The Regents Of The University Of California Method of modulating radical formation by mutant cuznsod enzymes
EP0969868A2 (en) 1997-03-18 2000-01-12 Ortho-Mcneil Pharmaceutical, Inc. Methods and kits for treating and diagnosing leiomyomas
US7863444B2 (en) 1997-03-19 2011-01-04 Abbott Laboratories 4-aminopyrrolopyrimidines as kinase inhibitors
US6723694B1 (en) 1997-05-21 2004-04-20 The Children's Medical Center Corp. Short peptides which selectively modulate intracellular signalling
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6096778A (en) 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
US20010006793A1 (en) 1998-03-20 2001-07-05 Mary-Ann Bjornsti Modulators of eukaryotic caspases
ZA200007412B (en) 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
EP1087782A4 (en) 1998-06-15 2001-09-12 Neuronz Ltd REGULATION OF TYROSINE HYDROXYLASE
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6319905B1 (en) 1998-12-29 2001-11-20 Cell Genesys, Inc. Method of controlling L-Dopa production and of treating dopamine deficiency
US6841567B1 (en) 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6624171B1 (en) 1999-03-04 2003-09-23 Smithkline Beecham Corporation Substituted aza-oxindole derivatives
US6312949B1 (en) 1999-03-26 2001-11-06 The Salk Institute For Biological Studies Regulation of tyrosine hydroxylase expression
US6297238B1 (en) 1999-04-06 2001-10-02 Basf Aktiengesellschaft Therapeutic agents
US6982265B1 (en) 1999-05-21 2006-01-03 Bristol Myers Squibb Company Pyrrolotriazine inhibitors of kinases
US20030125276A1 (en) 2001-11-08 2003-07-03 Isis Pharmaceuticals Inc. Antisense modulation of thyroid hormone receptor interactor 6 expression
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6797720B2 (en) 1999-12-03 2004-09-28 Ono Pharmaceutical Co., Ltd. 1,3,4-oxadiazoline derivative and an agent comprising its derivative as active ingredient
KR20020058078A (ko) 1999-12-03 2002-07-12 우에노 도시오 옥사디아졸 유도체 및 그 유도체를 유효 성분으로 하는 약제
US6334998B1 (en) 1999-12-07 2002-01-01 Parker Hughes Institute Estrogens for treating ALS
CO5271715A1 (es) 1999-12-21 2003-04-30 Sugen Inc 7-aza-indolin-2-onas sustituidas en 4 y su uso como inhibidores de proteiuna quinasa
US7108984B2 (en) 2000-01-12 2006-09-19 Mount Sinai School Of Medicine Methods of identifying modulators of the FGF receptor
US20020081663A1 (en) 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
KR20020067937A (ko) 2000-01-26 2002-08-24 오노 야꾸힝 고교 가부시키가이샤 벤젠 축합 헤테로환 유도체 및 그 유도체를 유효성분으로서 함유하는 약제
JP2001292778A (ja) 2000-04-11 2001-10-23 Inst Of Physical & Chemical Res トランケート型リーリンタンパク質およびそれをコードするｄｎａ
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
US20030211967A1 (en) 2001-05-07 2003-11-13 Bryant Henry Uhlman Method for selectively inhibiting ghrelin action
US6967237B2 (en) 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
AU2001269095A1 (en) 2000-06-26 2002-01-08 Bayer Aktiengesellschaft Regulation of human caspase-1-like protease
JP2002017361A (ja) 2000-07-04 2002-01-22 Inst Of Physical & Chemical Res リーリンタンパク質ｃｒ−５０エピトープ領域
JP4409135B2 (ja) * 2000-12-01 2010-02-03 武田薬品工業株式会社 生理活性物質含有製剤の製造法
US7381701B2 (en) 2001-02-15 2008-06-03 The Borad Of Trustees Of The University Of Illinois Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
WO2002077226A1 (fr) 2001-03-23 2002-10-03 Ono Pharmaceutical Co., Ltd. Recepteur ep1 de prostaglandine
WO2002083131A1 (en) 2001-04-13 2002-10-24 The Regents Of The University Of California Activators and ligands of ppar-beta/delta for the treatment of skin conditions
AU2002256359A1 (en) 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Antisense and anti-inflammatory based compositions to treat respiratory disorders
US20050182006A1 (en) 2001-05-18 2005-08-18 Sirna Therapeutics, Inc RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
US20040204368A1 (en) 2001-05-31 2004-10-14 Kazuyuki Ohmoto Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient
US7736677B2 (en) 2001-06-20 2010-06-15 Metaproteomics, Llc Xanthohumol and tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
EP2221376B1 (en) 2001-06-21 2012-11-21 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
WO2003004057A1 (en) 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
DE10134196B4 (de) 2001-07-13 2005-08-18 Forschungszentrum Karlsruhe Gmbh Technik Und Umwelt Pharmazeutische Zusammensetzung zur Hemmung der unkontrollierten Vermehrung und/oder Induzierung der Apoptose von Zellen
US7348140B1 (en) 2001-07-25 2008-03-25 Acadia Pharmaceuticals, Inc. Clinical indications for genotyping polymorphic variants of G-protein coupled receptors
EP1423133B1 (en) 2001-08-15 2009-01-14 Brown University Research Foundation Treatment of muscular dystrophies and related disorders
WO2003016343A2 (en) 2001-08-16 2003-02-27 Angiogene Inc. USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
JP2005501917A (ja) 2001-09-07 2005-01-20 ザ トラスティーズ オブ ボストン ユニバーシティ 免疫複合体関連疾患を処置するための方法および組成物
CN1633598A (zh) 2001-10-05 2005-06-29 科勒制药股份公司 Toll样受体3信号传导的激动剂和拮抗剂
US20030078199A1 (en) 2001-10-09 2003-04-24 Youmin Shu Human EphA6 gene and polypeptide
PT1445258E (pt) 2001-10-12 2009-07-02 Nippon Chemiphar Co Activador para o receptor delta activado por proliferador de peroxissoma
EP1442062A4 (en) 2001-10-18 2005-11-09 Genentech Inc METHOD FOR TREATING CARCINOMA
JP2005507927A (ja) 2001-10-30 2005-03-24 バイオジェン・アイデック・エムエイ・インコーポレイテッド パーキンソン病を処置するための方法および組成物
PL369738A1 (en) 2001-11-05 2005-05-02 Merck Patent Gmbh Hydrazono-malonitriles
US20030165485A1 (en) 2001-11-09 2003-09-04 Goran Bertilsson Functional role and potential therapeutic use of Reelin, Gas6 and Protein S in relation to adult neural stem or progenitor cells
WO2003047511A2 (en) 2001-11-29 2003-06-12 U.S. Department Of Veterans Affairs Use of gingko biloba extracts to promote neuroprotection and reduce weight loss
DK2298301T3 (en) 2001-12-06 2018-10-01 Fibrogen Inc MEDICINALS FOR TREATMENT OF ANEMIA ASSOCIATED WITH Kidney Disease
NZ533627A (en) 2001-12-19 2006-03-31 Itoham Foods Inc Remedies and/or preventatives for neurodegenerative diseases using VIP or PACAP peptides
EP1469878B1 (en) 2002-01-31 2011-03-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Fgfr agonists
US20030225098A1 (en) 2002-03-21 2003-12-04 Hirst Gavin C. Kinase inhibitors
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
BRPI0308663B8 (pt) 2002-03-22 2021-05-25 Applied Res Systems Ars Holding N V uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
EP1490696A2 (en) 2002-03-26 2004-12-29 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs)
IL149562A0 (en) 2002-05-09 2002-11-10 Prochon Ltd Fgf variants and methods for use thereof
EP1506786B1 (en) 2002-05-21 2016-11-23 Daiichi Sankyo Company, Limited Medicinal compositions containing ghrelin
WO2003103599A2 (en) 2002-06-05 2003-12-18 Sunesis Pharmaceuticals, Inc. Caspase-1 inhibitors and methods for their use
US20040022765A1 (en) 2002-07-31 2004-02-05 Isis Pharmaceuticals Inc. Antisense modulation of Ran GTPase activating protein 1 expression
WO2004004772A1 (ja) 2002-07-05 2004-01-15 Chugai Seiyaku Kabushiki Kaisha 糖尿病治療剤
TWI329112B (en) 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
EP1530635B1 (en) * 2002-08-01 2011-06-15 Noxxon Pharma AG Ghrelin binding nucleic acids
AU2003265349A1 (en) 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
EP1407760A1 (de) 2002-10-08 2004-04-14 Cognis France S.A. Verfahren zum Schutz der Haut gegen Alterung
US20070010658A1 (en) 2002-10-29 2007-01-11 Holtet Thor L Trimeric binding proteins for trimeric cytokines
AU2003290586B2 (en) 2002-11-04 2009-07-02 University Of Massachusetts Allele-specific RNA interference
AU2003295600A1 (en) 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
JP3810731B2 (ja) 2002-11-29 2006-08-16 独立行政法人科学技術振興機構 哺乳動物のＴｏｌｌ様受容体３に結合する新規アダプタータンパク質およびその遺伝子
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
EP1891966B1 (en) 2002-12-20 2012-02-15 H. Lundbeck A/S Modulation of activity of neurotrophins; screening method
CA2513584A1 (en) 2003-01-20 2004-08-05 Vib Vzw The use of yop proteins or rho gtpase inhibitors as caspase-1 inhibitors
US7354933B2 (en) 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
CA2515708A1 (en) 2003-02-11 2004-08-26 Transkaryotic Therapies, Inc. Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
US20040220270A1 (en) 2003-03-07 2004-11-04 The Jackson Laboratory Methods and composition of treating glaucoma by modulating tyrosinase/L-DOPA pathway
WO2004087066A2 (en) 2003-03-27 2004-10-14 Emory University Hif-1 inhibitors
US7253166B2 (en) 2003-04-22 2007-08-07 Irm Llc 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells
US20040242559A1 (en) 2003-04-25 2004-12-02 Aventis Pharma S.A. Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
JP4467518B2 (ja) 2003-04-30 2010-05-26 賢治 寒川 肝障害予防治療剤
WO2004098520A2 (en) 2003-05-01 2004-11-18 Irm Llc Compounds and compositions as protein kinase inhibitors
PT1636228E (pt) 2003-05-23 2009-02-02 Aeterna Zentaris Gmbh Novas piridopirazinas e sua utilização como moduladores de cinases
AU2004249904A1 (en) 2003-06-18 2004-12-29 Direvo Biotech Ag New biological entities and the pharmaceutical or diagnostic use thereof
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
MXPA05013922A (es) 2003-06-20 2006-02-24 Coley Pharm Group Inc Antagonistas de receptor tipo toll de molecula pequena.
US8592391B2 (en) 2003-07-01 2013-11-26 Andres Salazar Method for therapeutic, clinical and veterinary use poly-ICLC
WO2005007628A1 (en) 2003-07-11 2005-01-27 Bristol-Myers Squibb Company Tetrahydroquinoline derivatives as cannabinoid receptor modulators
US20090105149A1 (en) 2003-08-07 2009-04-23 Enkam Pharmaceuticals A/S Compounds comprising lpa
EP2060270A3 (en) 2003-10-16 2009-12-09 Imclone LLC Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof
EP1678320A2 (en) 2003-10-21 2006-07-12 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with arginyl aminopeptidase (aminopeptidase b)-like 1 (rnpepl1)
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
US7504506B2 (en) 2003-11-04 2009-03-17 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
WO2005048926A2 (en) 2003-11-13 2005-06-02 The General Hospital Corporation Methods for treating pain
WO2005048916A2 (en) 2003-11-20 2005-06-02 Biovitrum Ab Tetrahydrospiro-beta-carboline-1,3 '-pyrrolidine derivatives and their use in ghsr-related disorders
WO2005051425A1 (ja) 2003-11-26 2005-06-09 Daiichi Pharmaceutical Co., Ltd. プロカスパーゼ１活性化阻害剤
US20050171182A1 (en) 2003-12-11 2005-08-04 Roger Briesewitz Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
EP1697420A2 (en) 2003-12-19 2006-09-06 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
WO2005063761A1 (en) 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
CA2553261C (en) 2004-01-16 2014-03-18 Stefan Barth Immunokinases
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070281986A1 (en) 2004-02-03 2007-12-06 Collier Gregory R Methods and Compositions for Modulating Satiety
EP1720567A2 (en) 2004-02-10 2006-11-15 Innate Pharma Composition and method for the treatment of carcinoma
CA2555417A1 (en) 2004-02-13 2005-09-01 Boston Biomedical Research Institute Inhibition of fgf signaling
US20060058255A1 (en) 2004-03-01 2006-03-16 Jianzhu Chen RNAi-based therapeutics for allergic rhinitis and asthma
US20060211752A1 (en) 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
EP1730520A2 (en) 2004-03-24 2006-12-13 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with peroxisome proliferator activated receptor delta (ppard)
FR2868422B1 (fr) 2004-03-31 2006-07-14 Aventis Pharma Sa Nouveaux derives pyrrolo(2,3-b) pyridine, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
JP2007530703A (ja) 2004-04-01 2007-11-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド Ｍｓおよびその他の脱髄疾患を治療するためのペルオキシソーム増殖因子活性化受容体デルタアゴニストの使用
BRPI0508180A (pt) 2004-04-01 2007-08-07 Aventis Pharma Inc 1,3,4-oxadiazol-2-onas como moduladores de ppar delta e seu uso deste
WO2005096781A2 (en) 2004-04-06 2005-10-20 University Of Massachusetts Methods and compositions for treating gain-of-function disorders using rna interference
US20090075900A1 (en) 2004-04-08 2009-03-19 Sadakazu Therapeutic agent for motor neuron disease
US7838645B2 (en) * 2004-04-30 2010-11-23 University Of Maryland College Park Function of autophagy genes in cell death
US7357933B2 (en) 2004-05-05 2008-04-15 Enhan Technology Holdings International Co., Ltd. Sporoderm-broken germination-activated ganoderma lucidum spores for protection of dopaminergic neurons and treatment of Parkinson's disease
CA2565974A1 (en) 2004-05-14 2005-12-01 Receptor Biologix, Inc. Cell surface receptor isoforms and methods of identifying and using the same
WO2005115362A1 (en) 2004-05-15 2005-12-08 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
JP2008501628A (ja) 2004-06-02 2008-01-24 武田薬品工業株式会社 インドール誘導体およびがんの治療用途
WO2005120570A2 (en) 2004-06-03 2005-12-22 The University Of Maryland, Baltimore Therapeutic targeting of parc/ccl18 and its signaling in pulmonary fibrosis
EP1750746A1 (en) 2004-06-04 2007-02-14 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
US7102002B2 (en) 2004-06-16 2006-09-05 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ATE545655T1 (de) 2004-06-18 2012-03-15 Enkam Pharmaceuticals As Fgfr-bindende peptide
MX2007000770A (es) 2004-07-20 2007-03-26 Schering Corp Induccion de apoptosis en celulas tumorales que expresan el receptor tipo toll.
EP1621535A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621536A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1784390A2 (en) 2004-08-13 2007-05-16 Amgen Inc. Substituted benzofused heterocycles
EP1778726A4 (en) 2004-08-16 2009-03-18 Medimmune Inc INTEGRIN ANTAGONISTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-ASSAYED CYTOTOXICITY ACTIVITY
US20070280886A1 (en) 2004-09-09 2007-12-06 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
EP1791535B1 (en) 2004-09-17 2008-07-30 BioMAS Ltd. Novel tellurium compounds and their use as immunomodulators
FR2876103B1 (fr) 2004-10-01 2008-02-22 Aventis Pharma Sa Nouveaux derives bis-azaindoles, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
CA2585717A1 (en) 2004-10-27 2006-05-04 Medimmune Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2005327921A1 (en) 2004-11-01 2006-08-31 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function
CA2587676A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
EP1662259A1 (en) 2004-11-25 2006-05-31 Cellzome Ag Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases
WO2006058539A2 (en) 2004-11-30 2006-06-08 Gastrotech Pharma A/S Growth hormone secretagogue receptor 1a ligands
AR051836A1 (es) 2004-11-30 2007-02-14 Centocor Inc Antagonistas de receptor 3 simil toll metodos y usos
JP4939432B2 (ja) 2004-12-01 2012-05-23 ホワイトヘッド インスティテュート フォー バイオメディカル リサーチ α−シヌクレイン毒性のモジュレーター
US20090123426A1 (en) 2004-12-17 2009-05-14 Chiang Li Compositions for Bacterial Mediated Gene Silencing and Methods of Using the Same
US7834064B2 (en) 2005-01-03 2010-11-16 Andres Mario Salazar Clinical method for the immunomodulatory and vaccine adjuvant use of poly-ICLC and other dsRNAs
CA2593648A1 (en) 2005-01-10 2006-07-13 Research Development Foundation Targeted chimeric molecules for cancer therapy
WO2006076673A2 (en) 2005-01-14 2006-07-20 Regeneron Pharmaceuticals, Inc. Use of il-i antagonists to treat polymyalgia rheumatica and giant cell arteritis
US20060194821A1 (en) 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
US7560436B2 (en) 2005-02-22 2009-07-14 The Regents Of The University Of California Methods of treating gastrointestinal inflammation
JP2008531057A (ja) 2005-03-02 2008-08-14 ザ スクリップス リサーチ インスティテュート 自己免疫疾患および関連疾患の処置のための組成物および方法
EP1877424A4 (en) 2005-04-11 2010-09-29 Pharmagap Inc INHIBITORS OF PROTEIN KINASES AND USES THEREOF
WO2006122931A1 (en) 2005-05-20 2006-11-23 Biovitrum Ab (Publ) Beta-carboline derivatives and theri use as ghsr modulators
US20090074676A1 (en) 2005-05-23 2009-03-19 Smithkline Beecham Corporation Inhibition of p38 MAPK For Treatment Of Obesity
EP1924294A4 (en) 2005-05-24 2010-11-03 Isis Pharmaceuticals Inc COMPOSITIONS AND ITS USES AGAINST PTPRU
JP2009500430A (ja) 2005-07-11 2009-01-08 シーバイオ リミテッド シャペロニン１０により誘導される免疫調整方法
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2620351C (en) 2005-08-31 2015-04-21 Universite Laval Antibodies and their use in the treatment, prevention and diagnosis of a disease associated with sod1 abnormalities
CN101277714B (zh) 2005-09-06 2013-01-30 三一治疗公司 治疗免疫介导的神经疾病的方法
FR2891273B1 (fr) 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
JP5517454B2 (ja) 2005-09-30 2014-06-11 スシネキス インク Ｃ型肝炎感染の治療及び予防のための方法及び医薬組成物
EP1934201A1 (en) 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US20070112031A1 (en) 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
EP2982679A1 (en) 2005-10-12 2016-02-10 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
JP2009511610A (ja) 2005-10-20 2009-03-19 シービーアイオー リミテッド 過敏症治療
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
EP1945820B1 (en) 2005-10-27 2013-08-28 Janssen Biotech, Inc. Toll like receptor 3 modulators, methods and uses
PT1945657E (pt) 2005-10-28 2012-02-02 Janssen Biotech Inc Muteínas dos locais de glicosilação de tlr3 e métodos de utilização
WO2007062119A1 (en) 2005-11-23 2007-05-31 Auspex Pharmaceuticals, Inc. Substituted aryloxypropylamines with serotoninergic and/or norepinephrinergic activity
PT1954669E (pt) 2005-12-01 2015-10-23 Auspex Pharmaceuticals Inc Feniletilaminas substituídas com actividade serotoninérgica e/ou norepinefrinérgica
US20070259827A1 (en) 2006-01-25 2007-11-08 University Of Massachusetts Compositions and methods for enhancing discriminatory RNA interference
WO2007089607A2 (en) 2006-01-26 2007-08-09 University Of Massachusetts Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
BRPI0707302B8 (pt) 2006-01-27 2021-05-25 Fibrogen Inc compostos de cianoisoquinolina que atuam no dano tecidual associado com isquemia, hipóxia e anemia, bem como composição farmacêutica que os compreende
CN101379060B (zh) 2006-02-10 2012-05-23 转化技术制药公司 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法
WO2007098099A2 (en) 2006-02-16 2007-08-30 Discogen, Llc Method of treating a subject suffering from degenerative disc disease using a matrix metalloprotease inhibitor
WO2007103048A2 (en) 2006-03-01 2007-09-13 Regents Of The University Of Colorado Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
EP1834953A1 (en) 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
EP2001475B1 (en) * 2006-03-15 2018-11-14 Michael O. Thorner Methods for treating sarcopenia with a growth hormone secretagogue
US20070232556A1 (en) 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
BRPI0710527B8 (pt) 2006-04-04 2021-05-25 Fibrogen Inc compostos de pirrolo- e tiazolo-piridina e composição farmacêutica que os compreende
US20070249519A1 (en) 2006-04-20 2007-10-25 Kalypsys, Inc. Methods for the upregulation of glut4 via modulation of ppar delta in adipose tissue and for the treatment of disease
EP2021015A2 (en) 2006-04-28 2009-02-11 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
US7772248B2 (en) 2006-06-05 2010-08-10 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted imidazopyridine compounds with hypnotic effects
JP2009539866A (ja) 2006-06-05 2009-11-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド 置換エリスロマイシンアナログの調製および有用性
US20070287734A1 (en) 2006-06-09 2007-12-13 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted pyrazole compounds with cannabinoid receptor activity
RU2008152193A (ru) 2006-06-15 2010-07-20 Бёрингер Ингельхайм Интернациональ Гмбх (De) 2-амино-4-аминоалкиленаминопиримидины
RU2008152195A (ru) 2006-06-15 2010-07-20 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) 2-анилино-4-(гетероциклил)аминопиримидины, как ингибиторы протеинкиназы с-альфа
AU2007261399A1 (en) 2006-06-20 2007-12-27 Metaproteomics, Llc Reduced isoalpha acid based protein kinase modulation cancer treatment
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
WO2008011621A2 (en) 2006-07-21 2008-01-24 The Penn State Research Foundation Protein kinase c zeta inhibition to treat vascular permeability
WO2008016677A2 (en) 2006-08-02 2008-02-07 Auspex Pharmaceuticals, Inc. Preparation and utility of deuterated amphetamines
EP2049117A4 (en) 2006-08-08 2010-08-25 Auspex Pharmaceuticals Inc PREPARATION AND USE OF SUBSTITUTED CHINAZOLIN COMPOUNDS WITH ALPHA-ADRENERGER BLOKING EFFECT
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CA2661302A1 (en) 2006-08-16 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of opioid analgesics
US20080145313A1 (en) 2006-08-30 2008-06-19 Genesis Research & Development Corporation Limited Compositions and Methods for the Treatment and Prevention of Neoplastic Disorders
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
WO2008033747A2 (en) 2006-09-11 2008-03-20 Curis, Inc. Multi-functional small molecules as anti-proliferative agents
CA2666149A1 (en) 2006-10-19 2008-04-24 Auspex Pharmaceuticals, Inc. Substituted indoles
US9375440B2 (en) 2006-11-03 2016-06-28 Medtronic, Inc. Compositions and methods for making therapies delivered by viral vectors reversible for safety and allele-specificity
US20080132555A1 (en) 2006-11-28 2008-06-05 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted phenyltetrazoles
US20080146573A1 (en) 2006-12-04 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted oxzolidinones
WO2008073863A2 (en) 2006-12-08 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted allylamines
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
US20080241289A1 (en) 2007-02-23 2008-10-02 Auspex Pharmaceuticals, Inc. Preparation and utility of non-nucleoside reverse transcriptase inhibitors
SI2125698T1 (sl) 2007-03-15 2016-12-30 Auspex Pharmaceuticals, Inc. Devterirani d9-venlafaksin
WO2008113100A1 (en) * 2007-03-16 2008-09-25 Novogen Research Pty Ltd Method for inducing autophagy
AU2008232425A1 (en) 2007-04-02 2008-10-09 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
CN101730694A (zh) 2007-04-10 2010-06-09 奥斯拜客斯制药有限公司 用于治疗高血压的取代的氘富集的噻吩
US20080255200A1 (en) 2007-04-11 2008-10-16 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
WO2008131219A1 (en) 2007-04-18 2008-10-30 Auspex Pharmaceuticals, Inc. Substituted anthranilic acids
BRPI0809843A2 (pt) 2007-04-26 2014-09-23 Auspex Pharmaceuticals Inc "composto, composição farmacêutica e uso de um composto"
US20080280991A1 (en) 2007-05-08 2008-11-13 Auspex Pharmaceuticals, Inc. Substituted naphthalenes
WO2008141057A1 (en) 2007-05-08 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
WO2008143835A1 (en) * 2007-05-15 2008-11-27 Yale University Ghrelin protects substantia nigra dopamine neurons
WO2008144602A1 (en) 2007-05-18 2008-11-27 Auspex Pharmaceuticals, Inc. Deuterated zamifenacin derivatives
WO2008147956A2 (en) 2007-05-25 2008-12-04 Centocor, Inc. Toll-like receptor 3 modulators and uses thereof
US7745665B2 (en) 2007-06-04 2010-06-29 Auspex Pharmaceuticals, Inc. Substituted phenethylamines
EP2166849A4 (en) 2007-06-11 2010-09-15 Miikana Therapeutics Inc SUBSTITUTED PYRAZOL COMPOUNDS
AU2008266124A1 (en) 2007-06-13 2008-12-24 Auspex Pharmaceuticals, Inc. Substituted piperazines
WO2008157786A1 (en) 2007-06-20 2008-12-24 Auspex Pharmaceutical, Inc. Substituted n-aryl pyridinones as fibrotic inhibitors
WO2009006413A1 (en) 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
EP3889261A1 (en) 2007-08-27 2021-10-06 1Globe Health Institute LLC Compositions of asymmetric interfering rna and uses thereof
WO2009032843A2 (en) 2007-09-06 2009-03-12 Auspex Pharmaceuticals, Inc. Deuterated ethambutols and their use
US20090088401A1 (en) 2007-09-27 2009-04-02 Andres Salazar In-situ cancer autovaccination with intratumoral stabilized dsRNA viral mimic

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008152816A1 (en) * 2007-06-14 2008-12-18 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of vegfr1 by smyd3

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014045870; Ｊｉａ-Ｎｉｎｇ　Ｚｏｕ　ｅｔ　ａｌ: Ｃａｎｃｅｒ　Ｌｅｔｔｅｒｓ ｖｏｌ．２８０，　ｎｏ．１, 20090718, ｐ．７８-８５ *

Also Published As

Publication number Publication date
CA2774998A1 (en) 2011-04-07
US20160194631A1 (en) 2016-07-07
AU2010300531A1 (en) 2012-05-24
US20120315244A1 (en) 2012-12-13
KR20120082906A (ko) 2012-07-24
WO2011041584A2 (en) 2011-04-07
JP2013506686A (ja) 2013-02-28
MX2012003770A (es) 2012-08-03
WO2011041584A3 (en) 2011-05-26
WO2011041582A3 (en) 2011-09-29
WO2011041582A2 (en) 2011-04-07
BR112012007137A2 (pt) 2015-09-15
EP2483406A2 (en) 2012-08-08
AU2016201939A1 (en) 2016-04-21
EP2483407A2 (en) 2012-08-08
JP2016040297A (ja) 2016-03-24
US20140004108A1 (en) 2014-01-02
CA2774999A1 (en) 2011-04-07
CN102869775A (zh) 2013-01-09
US20120301463A1 (en) 2012-11-29
BR112012007160A2 (pt) 2018-03-13
CN102639700A (zh) 2012-08-15
RU2012117230A (ru) 2013-11-10

Similar Documents

Publication Publication Date Title
JP2013506687A (ja) オートファジー促進遺伝子産物の変調によりオートファジーを変調する方法
EP3500307B1 (en) Use of vcp inhibitor and oncolytic virus in the preparation of an anti-tumor drug
JP2021020951A (ja) セロトニン放出ホルモン、アドレナリン放出ホルモン、ノルアドレナリン放出ホルモン、グルタミン酸放出ホルモンおよび副腎皮質刺激ホルモン放出ホルモン関連の医学的状態の処置および診断のためのマイクロｒｎａおよび該マイクロｒｎａを含む組成物
US11332540B2 (en) Use of Circ-CDH1 inhibitors
CN112011614B (zh) Kmt5a在调控胶质瘤干细胞特性及胶质瘤诊治中的应用
Ono et al. Notch2 negatively regulates myofibroblastic differentiation of myoblasts
Wang et al. Temporal changes in inflammatory mitochondria-enriched microRNAs following traumatic brain injury and effects of miR-146a nanoparticle delivery
Gavet et al. Regulation and subcellular localization of the microtubule‐destabilizing stathmin family phosphoproteins in cortical neurons
CN116368384A (zh) 用于巨噬细胞调节的化合物、靶标和途径
Xu et al. The SWI/SNF-related, matrix associated, actin-dependent regulator of chromatin A4 core complex represses respiratory syncytial virus-induced syncytia formation and subepithelial myofibroblast transition
EP3921031A1 (en) Methods and compositions for modulating blood-brain barrier
US20230366033A1 (en) Methods for treating cancers with inhibitors targeting the role of grb2 in dna repair
KR20200137253A (ko) Fes 저해제를 포함하는 방사선 민감도 증진용 조성물
US20050265997A1 (en) Cancer treatment method by inhibiting MAGE gene expression or function
Park et al. Effect of Synthetic CaM and NFAT Oligodeoxynucleotide on MPP+-Stimulated Mesencephalic Neurons
US10870854B2 (en) Inhibitory RNA-based therapeutics targeting ANLN for cancer treatment
CN121041445A (zh) 抑制DVL1表达的miR-1247-5p在治疗骨关节炎中的应用
CN121775146A (zh) Fas-as1和otud1在制备提高鼻咽癌吉西他滨治疗敏感性的药物中的应用
CN117230198A (zh) Wnt10a和slco4a1-as1在胶质瘤诊治中的应用
WO2015187929A1 (en) Treatment of fragile x syndrome by inhibition of cdh1-apc
HK40010205B (en) Use of vcp inhibitor and oncolytic virus in the preparation of an anti-tumor drug
Blenkinsop et al. FOXS1 is a Master Regulator of Pathological Epithelial to Mesenchymal Transition in Human Epithelia
Neuro-Oncology et al. Identification of growth hormone receptor as a relevant target for precision medicine in low-EGFR expressing glioblastoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150707